DRKS00032279招募中1 期
CAR-T cells in SysTemic B celL mediated autoimmunE Disease - CASTLE
Friedrich-Alexander-Universität Erlangen-Nürnberg, Medizinische Fakultät0 个研究点目标入组 24 人开始时间: 2023年7月18日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- N/a: Single Arm Study
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 one（—）
- 性别
- All
入选标准
- •General inclusion criteria
- •Subjects must understand and voluntarily sign an informed consent form including writ-ten consent for data protection,
- •Adults aged = 18 years at time of consent,
- •Adequate renal (eGFR > 30 ml/min/m2), liver (no Child Pugh C), heart (at worst NYHA III, EF > 30%) and pulmonary (FV and DLCO > 30%) function,
- •Male subjects unless surgically sterile, must agree to use two acceptable methods for contraception (e.g. spermicide and condom) during the trial and refrain from fathering a child starting from the time of signing the Informed Consent Form (ICF) until 12 months after dosing of the IMP,
- •Females of childbearing potential (FCBP) must have a negative urine pregnancy test at screening and must agree to use a highly effective contraceptive method (Pearl in-dex <1) starting from the time of signing the ICF and for 12 months after dosing of the IMP,
- •Must be able to adhere to the study visit schedule and other protocol requirements,
- •Double vaccination against SARS-CoV-2 or SARS-CoV-2 within the last 6 months.
- •Disease-specific inclusion criteria
- •SLE subjects
- •Fulfilling the 2019 ACR/EULAR classification criteria of SLE ([64]),
- •Positivity of anti-dsDNA (> 4 U/l), anti-histone (+ or more), anti-nucleosome (+ or more) or anti-Sm antibodies (+ or more),
- •Active disease at screening, defined as = 1 organ system with a British Isles Lupus Assessment (BILAG) A score (severe disease activity) or = 2 organ systems with a BILAG B score (moderate disease activity) ([58]),
- •Insufficient response or intolerance/ contraindication to glucocorticoids and to at least 2 of the following treatments: hydroxychloroquine, mycophenolate mofetil, belimumab, methotrexate, rituximab, cyclophosphamide. Insufficient response is defined as having increased disease activity based on the definition explained in the previous bullet point.
- •SSc subjects
- •Fulfilling the 2013 ACR/EULAR classification criteria of SSc ([14]),
- •Positivity (+ or more) for at least one SSc-specific parameter (Scl70, RNA polymerase, Th/To, RP11/12, U3RNP autoantibodies),
- •Signs for fast progression including (i) disease duration = 5 years (from onset of first non-Raynaud manifestation), (ii) mRSS score 10-35 at screening, (iii) elevated acute phase reactant levels (CRP = 6 mg/L, ESR = 28mm/h or platelet count = 330 G/L), (iii) mRSS increase = 3 units or involvement of one new body area or mRSS increase = 2 units in one body area or = 1 tendon friction rub over 6 months ([56]),
- •Insufficient response or intolerance/ contraindication to at least 2 of the following treat-ments: mycophenolate mofetil, azathioprine, nintedanib, methotrexate, rituximab. In-sufficient response is defined as having increased disease activity based on the defini-tion explained in the previous bullet point.
- •DM/PM subjects
- •Fulfilling the 2017 ACR/EULAR classification criteria for probable or definite DM or PM ([65]),
- •Presence of active myositis in muscle biopsy or muscle MRI and/or signs of interstitial lung disease related to DM/PM,
- •Positivity (+ or more) for at least one myositis-specific antibody (aminoacyl tRNA syn-thetases, Mi2, MDA5, SAE, SRP, ARS, HMGCR, MJ, TIF1gamma),
- •Muscle weakness as define by MMT < 142 and 2 of the following criteria: VAS patients Global =2cm, VAS physician Global = 2cm, HAQ > 0.25, at least one muscle enzyme > 1.3 times upper limit of normal, VAS global extra muscular activity = 2cm,
- •Insufficient response or into
排除标准
- •Clinically suitability for a less burdensome and/or approved therapeutic approach, as judged by the investigator,
- •ANC < 1.000/mm3, ALC < 500/mm3 or hemoglobin < 8g/dl, absolute CD3+ T cell count < 100/µl,
- •Uncontrolled severe concomitant disease, such as cancer (except basal or squamous cell skin cancer) and diabetes mellitus,
- •Severely impaired renal (eGFR = 30 ml/min/m2), liver (Child Pugh C), heart (NYHA IV, EF = 30%) and pulmonary (FV and DLCO = 30%) function,
- •Any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study,
- •Prior treatment with anti-CD19 antibody therapy, adoptive T cell therapy or any prior gene therapy product (e.g. CAR T cell therapy),
- •History of bone marrow/ hematopoietic stem cell or solid organ transplantation,
- •Any concomitant severe active infection, e.g. HIV, hepatitis B or C, SARS-CoV 2 (COVID 19), or active tuberculosis as defined by a positive Quantiferon TB-test. If presence of latent tuberculosis is established then treatment according to local guidelines must have been initiated prior to enrollment,
- •Diagnosis of severe neuropsychiatric SLE, inclusion body myositis or limited SSc,
- •Pregnant or lactating females,
- •Females who are intending to conceive during the study,
- •Known hypersensitivity to any drug components,
- •Malignancy in the last 5 years before screening,
- •Requirement for immunization with live vaccine during the study period or within 14 days preceding leukapheresis,
- •Subjects who are younger than 18 years or are incapable to understand the aim, importance and consequences of the study and to give legal informed consent,
- •Have a history of alcohol or substance abuse within the preceding 6 months that, in the opinion of the Investigator, may increase the risks associated with study participation or study agent administration, or may interfere with interpretation of results,
- •Subjects who possibly are dependent on the Sponsor, the Principal Investigator or Investigator (e.g. family members).
研究者
相似试验
招募中
1 期
CAR-T cells in systemic B cell mediated autoimmune disease - CASTLECTIS2024-516819-24-00niversitaetsklinikum Erlangen AöR24
招募中
1 期
CAR-T Cells in Systemic B Cell Mediated Autoimmune DiseaseSystemic Lupus ErythematosusPolymyositisSystemic SclerosisDermatomyositisNCT06347718Miltenyi Biomedicine GmbH24
尚未招募
1 期
CAR-T Cells Targeting Autoimmune DiseasesAutoimmune DiseasesNCT05459870Shenzhen Geno-Immune Medical Institute30
尚未招募
不适用
A Study of CAR-T Cells Targeting Autoimmune DiseasesAutoimmune DiseasesNCT06661811Beijing Boren Hospital12
招募中
不适用
nderstanding B cell biology in auto-immune diseases.Autoimmune diseasesRheumatic diseases10003816NL-OMON53019eids Universitair Medisch Centrum1,095